By submitting this form, you are agreeing to the Terms of Use and Privacy Policy.
Patients with heart failure or syndrome of inappropriate antidiuretic hormone (SIADH) who have hyponatremia (low sodium in the blood) are treated with tolvaptan (SIADH). Adults who are at risk of developing autosomal dominant polycystic kidney disease can also take tolvaptan to prevent the rapid deterioration of their kidney function (ADPKD).
A group of drugs known as vasopressin V2 receptor antagonists includes tolvaptan. It functions by raising the volume of water passed by the body in the form of urine and reducing the development of kidney cysts.
Peak effects happen four to eight hours after ingestion, with the commencement of action occurring two to four hours after taking the dose. The bioavailability, start, or duration of effects of tolvaptan do not appear to be impacted by taking it with food.
For adults exclusively, tolvaptan is recommended. Tolvaptan has only been used to treat a small fraction of PCOS patients older than 50 years of age in clinical trials, so caution should be exercised before starting treatment at ages older than.
According to clinical tests, the medication preserved renal function and decreased cyst formation when compared to a placebo. According to estimates, four years of tolvaptan treatment in individuals at risk for rapid development could postpone the requirement for renal replacement therapy (dialysis or transplant) by one year.
The Global TOLVAPTAN market accounted for $XX Billion in 2023 and is anticipated to reach $XX Billion by 2030, registering a CAGR of XX% from 2024 to 2030.
Otsuka Pharmaceutical Co., Ltd. (Otsuka) announces that tolvaptan, the first medication available to slow kidney function decline in adults at risk of rapidly progressing autosomal dominant polycystic kidney disease, has received approval from the U.S. Food and Drug Administration (FDA) (ADPKD).
Dialysis or kidney transplantation may be necessary as a result of the effects of ADPKD, a hereditary condition. It is a gradually crippling and frequently painful condition in which the kidneys gradually swell with fluid cysts.
The majority of individuals develop renal failure as a result of these cysts’ enlargement and impairment of the kidneys’ normal function. About 140,000 Americans have been diagnosed with ADPKD, which affects families over several generations.because there is a 50% possibility that each of a parent’s offspring may get ADPKD.
Two crucial trials that lasted one year and three years, respectively, proved tolvaptan’s effectiveness. The change in eGFR from pretreatment baseline to post-treatment follow-up, annualised by dividing by each subject’s treatment period, served as the primary endpoint in the one-year REPRISE research.
